Literature DB >> 19682236

von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size.

S-Y Jin, C G Skipwith, D Shang, X L Zheng.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19682236      PMCID： PMC2755043          DOI： 10.1111/j.1538-7836.2009.03570.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  20 in total

1.  ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.

Authors:  Jing-fei Dong; Joel L Moake; Aubrey Bernardo; Kazuo Fujikawa; Chalmette Ball; Leticia Nolasco; José A López; Miguel A Cruz
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

2.  Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.

Authors:  Xinglong Zheng; Kenji Nishio; Elaine M Majerus; J Evan Sadler
Journal:  J Biol Chem       Date:  2003-06-05       Impact factor: 5.157

Review 3.  Thrombotic thrombocytopenic purpura: the systemic clumping "plague".

Authors:  Joel L Moake
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

Review 4.  von Willebrand factor: two sides of a coin.

Authors:  J E Sadler
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

5.  Shear stress enhances the proteolysis of von Willebrand factor in normal plasma.

Authors:  H M Tsai; I I Sussman; R L Nagel
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

6.  P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface.

Authors:  Arnoldo Padilla; Joel L Moake; Aubrey Bernardo; Chalmette Ball; Yongtao Wang; Maneesh Arya; Leticia Nolasco; Nancy Turner; Michael C Berndt; Bahman Anvari; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

7.  Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.

Authors:  H M Tsai
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

8.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

Authors:  M Furlan; R Robles; B Lämmle
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

9.  Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.

Authors:  Thomas J Raife; Wenjing Cao; Bonnie S Atkinson; Bruce Bedell; Robert R Montgomery; Steven R Lentz; George F Johnson; X Long Zheng
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

10.  Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization.

Authors:  D D Wagner; V J Marder
Journal:  J Cell Biol       Date:  1984-12       Impact factor: 10.539
View more
  14 in total

1.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 2.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 3.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

4.  Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.

Authors:  Jialing Bao; Juan Xiao; Yingying Mao; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-12-19       Impact factor: 8.311

5.  Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.

Authors:  Monisha Kumar; Wenjing Cao; Jenny K McDaniel; Huy P Pham; Dheeraj Raju; Kelsey Nawalinski; Suzanne Frangos; David Kung; Eric Zager; Scott E Kasner; Joshua M Levine; X Long Zheng
Journal:  Thromb Haemost       Date:  2017-01-19       Impact factor: 5.249

6.  Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis.

Authors:  Juan Xiao; Sheng-Yu Jin; Jing Xue; Nicoletta Sorvillo; Jan Voorberg; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-28       Impact factor: 8.311

7.  A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura.

Authors:  Yue Han; Juan Xiao; Erica Falls; X Long Zheng
Journal:  Transfusion       Date:  2011-01-20       Impact factor: 3.157

Review 8.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

9.  Fluid Mechanics of Blood Clot Formation.

Authors:  Aaron L Fogelson; Keith B Neeves
Journal:  Annu Rev Fluid Mech       Date:  2015-01-01       Impact factor: 18.511

10.  Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.

Authors:  Sheng-Yu Jin; Christopher G Skipwith; X Long Zheng
Journal:  Blood       Date:  2010-01-14       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.